Navigation Links
BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
Date:3/11/2008

NOVATO, Calif., March 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jeff Cooper, Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 28th Annual Healthcare Conference in Boston on Tuesday, March 18, 2008 at 10:15 a.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R) and Naglazyme(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the 2016 ... Texas. , Scott Pettigrew, Vice President and Chief Security Officer of HMS, ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... With May flowers, summer is just around ... it means a welcome respite from school and the ability to play all day and ... for their children or watch the little tykes themselves. Summer also means trips to the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ACLS Certification Institute, a ... new referral program, giving participants incentive for spreading the word about the Institute’s ... know many professionals share resources with their friends and colleagues,” said Vonda Andrews, ...
(Date:5/5/2016)... ... 2016 , ... Pigment Laser Tattoo Removal Center is proud to be the ... laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This new laser ... the market. Jeremy Miller, Tattoo Artist and former reality show contestant on Spike ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... ctellez(at)msnva.org , The Medical Society of Northern Virginia, Announces DoctorsTelemed?, A ... The Medical Society of Northern Virginia (MSNVA) launches DoctorsTelemed?, a telemedicine solution ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 In ... a series of free workshops across ... requirements for Good Distribution Practices (GDP). Good ... ensures that products are consistently stored, transported and handled ... (MA) or product specification. Only a few years ago, ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
Breaking Medicine Technology: